Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
21.77 AUD | +2.01% | +6.17% | -14.54% |
05-09 | Neuren Pharmaceuticals Partner Acadia Pharmaceuticals Posts US DAYBUE Sales of $75.9 Million | MT |
04-24 | Neuren Pharmaceuticals Posts AU$243 Million Cash, Short-Term Investments | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.54% | 1.71B | |
+31.37% | 588B | |
-2.60% | 364B | |
+20.83% | 326B | |
+5.69% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.77% | 167B | |
+0.10% | 161B |
- Stock Market
- Equities
- NEU Stock
- News Neuren Pharmaceuticals Limited
- Neuren Pharmaceuticals Concludes Enrollment for Phase 2 Trial in Pitt Hopkins Syndrome